Abbott Laboratories — Oct 15, 2025 release

14.4  16.7  12.2  12.4  5.6  14.1  0.3  23.2      International 10.7  3.2  10.5  14.6  4.0  11.2  20.8  14.9  Page 6 of 20 ABBOTT'S FINANCIAL GUIDANCE Abbott reaffirms previously provided full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales, or 6.0% to 7.0%, when including COVID-19 testing-related sales. Abbott also reaffirms the midpoint of the previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18, which reflects double-digit growth at the midpoint. Abbott has not provided the related GAAP financial measures on a forward-looking basis for these forward-looking non-GAAP financial measures because the company is unable to predict with reasonable certainty and without unreasonable effort the timing and impact of certain items such as restructuring and cost reduction initiatives, charges for intangible asset impairments, acquisition-related expenses, and foreign exchange, which could significantly impact Abbott's results in accordance with GAAP. ABBOTT DECLARES 407 th  CONSECUTIVE QUARTERLY DIVIDEND On Sept. 19, 2025, the board of directors of Abbott declared the company's quarterly dividend of $0.59 per share. Abbott's cash dividend is payable Nov. 17, 2025, to shareholders of record at the close of business on Oct. 15, 2025. Abbott has increased its dividend payout for 53 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at leas